Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Diabetes. Insights from the extended follow-up of the ACCORD trial.

Zoungas S, Woodward M.

Nat Rev Cardiol. 2011 Jun;8(6):308-10. doi: 10.1038/nrcardio.2011.65. Epub 2011 Apr 19.

PMID:
21502962
4.
5.

[Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials].

Radermecker RP, Philips JC, Jandrain B, Paquot N, Scheen AJ.

Rev Med Liege. 2008 Jul-Aug;63(7-8):511-8. French.

6.
7.

[Intensive glycemia control of type-2 diabetes mellitus: a real A(D)VANCe or a deep dis(ACCORD)?].

Lambiel J, Fumeaux T.

Rev Med Suisse. 2008 Aug 6;4(166):1734. French. No abstract available.

PMID:
18777740
8.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial--clinical implications.

Ismail-Beigi F.

Clin Chem. 2011 Feb;57(2):261-3. doi: 10.1373/clinchem.2010.148288. Epub 2010 Oct 25. No abstract available.

9.

Managing cardiovascular risk in patients with diabetes.

Rydén L.

Heart. 2000 Sep;84 Suppl 1:i23-5:discussion i50. No abstract available.

10.

[Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].

Füchtenbusch M, Hummel M.

MMW Fortschr Med. 2008 Apr 24;150(17):42-4. German. No abstract available.

PMID:
18510157
11.
12.

[Comment from the diabetology viewpoint].

Stahl M.

Praxis (Bern 1994). 2008 Aug 27;97(17):943-4. German. No abstract available.

PMID:
18777777
13.

[Questions for practicing internists].

Zinnenlauf S.

Praxis (Bern 1994). 2008 Aug 27;97(17):945-6. German. No abstract available.

PMID:
18777778
14.

Diabetes: intensive glucose-lowering therapy-weighing up the evidence.

Cohen N.

Nat Rev Endocrinol. 2010 Jan;6(1):9-10. doi: 10.1038/nrendo.2009.226. No abstract available.

PMID:
20010962
15.

Why are we doing cardiovascular outcome trials in type 2 diabetes?

Menon V, Aggarwal B.

Cleve Clin J Med. 2014 Nov;81(11):665-71. doi: 10.3949/ccjm.81gr.14005.

PMID:
25368216
16.

Type 2 diabetes: increased mortality with low HbA1c.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):23.

PMID:
23373083
17.

Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease.

Smilowitz NR, Donnino R, Schwartzbard A.

Circulation. 2014 Jun 3;129(22):2305-12. doi: 10.1161/CIRCULATIONAHA.113.006985. Review. No abstract available.

18.

[Acute blood sugar peaks endanger blood vessels: the postprandial situation to be controlled better].

[No authors listed]

MMW Fortschr Med. 2006 Jun 29;148(26):57. German. No abstract available.

PMID:
16875385
19.

Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD.

Hoogwerf BJ; Action to Control Cardiovascular Risk in; Diabetes Study Group.

Cleve Clin J Med. 2008 Oct;75(10):729-37. Review.

PMID:
18939389
20.

Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?

Boussageon R, Gueyffier F, Cornu C.

Diabetes Metab. 2014 Jun;40(3):169-75. doi: 10.1016/j.diabet.2013.12.010. Epub 2014 Feb 3. Review.

PMID:
24503191

Supplemental Content

Support Center